# NCT02563002 (NCT02563002)

> Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02563002
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Colorectal Carcinoma
- Interventions: mFOLFOX6; FOLFIRI; Pembrolizumab; Bevacizumab; Cetuximab
- Enrollment: 307
- Primary outcome: Progression-Free Survival (PFS) Per RECIST1.1 As Assessed by Central Imaging Vendor
- Primary outcome: Overall Survival (OS)

## Commentary we found

- Podcasts: 66
- X threads: 65
- YouTube: 60

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=nct02563002

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02563002", "email": "<work email>"}; the inbox owner confirms by the emailed link.